查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2080400

中樞神經系統藥物市場：2026-2032年全球市場預測（依藥物類別、劑型、病患類型、作用機轉、治療領域、通路、處方格式及銷售模式分類）

Central Nervous System Drugs Market by Drug Class, Dosage Form, Patient Type, Mechanism Of Action, Therapeutic Area, Distribution Channel, Prescription Type, Sales Model - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，中樞神經系統藥物市場將成長至 635.9 億美元，複合年成長率為 10.85%。

主要市場統計數據
基準年 2025 309.1億美元
預計年份：2026年 341.6億美元
預測年份：2032年 635.9億美元
複合年成長率 (%) 10.85%

中樞神經系統藥物市場概覽

由於神經系統和精神疾病構成龐大、持續且臨床複雜的疾病負擔，中樞神經系統（CNS）藥物仍然是全球醫療保健的重要支柱。世界衛生組織（WHO）將神經系統疾病列為全球主要致殘原因之一，而憂鬱症、癲癇、偏頭痛、多發性硬化症、帕金森氏症、阿茲海默症、思覺失調症和神經性疼痛等疾病持續存在著巨大的治療需求。

中樞神經系統（CNS）製藥業的變革性變化

中樞神經系統（CNS）製藥業正從廣泛的症狀治療轉向精準的神經病學和精神病學。遺傳學、腦脊髓液生物標記、血液生物標記、數位表現型分析和影像學的進步，正在改善疾病的患者分層，而疾病的異質性曾導致以往臨床試驗失敗率居高不下。

人工智慧（AI）對中樞神經系統（CNS）藥物研發的累積影響。

人工智慧（AI）並非單一工具，而是對中樞神經系統（CNS）藥物的整個價值鏈產生累積影響。 AI驅動的標靶發現、蛋白質結構建模、化合物篩檢和多組體學分析正在幫助研究人員評估與神經退化、神經發炎、突觸功能、癲癇機制、疼痛訊號傳導以及精神疾病機制相關的生物學路徑。

關於中樞神經系統（CNS）藥物的關鍵區域見解

北美憑藉其先進的研究基礎設施、高普及率的專業醫療服務、廣泛的臨床實驗室網路以及與美國食品藥物管理局( FDA) 和加拿大衛生部建立的強力的監管夥伴關係，仍然是中樞神經系統 (CNS) 醫學領域的領先地區。該地區受益於完善的神經病學和精神病學臨床體系、活躍的學術研究中心以及擴大利用真實世界數據 (RWE) 來評估治療的安全性和療效。歐洲同樣具有影響力，這得益於歐洲藥品管理局 (EMA)、國家醫保報銷機制、大規模的學術神經病學網路以及對神經退化性疾病研究的持續投入。在整個歐洲，衛生技術評估機構繼續高度重視療效比較、長期安全性以及可證實的患者獲益。

來自東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約等主要組織的見解

歐盟為中樞神經系統（CNS）藥物提供了最完善的監管和醫療評估環境之一，並日益重視療效比較、藥物安全監測、安全監督以及成員國之間的公平取得。七國集團（G7）為全球大部分中樞神經系統研究經費、藥物創新、先進醫療服務和監管科學提供支持，並在疾病修正治療、神經系統專科治療和循證精神藥物療法的引入方面發揮著核心作用。

重點中樞神經系統（CNS）藥物市場的關鍵國家洞察

美國擁有強大的資本市場、大規模的臨床試驗網路和完善的食品藥物管理局核准流程，在中樞神經系統（CNS）藥物的商業化、臨床開發、監管創新和高附加價值專科療法的引進方面處於世界領先地位。加拿大則強調實證報銷、醫療技術評估和准入管理。同時，墨西哥和巴西是重要的拉丁美洲市場，其公共和私人醫療保健系統影響癲癇、精神疾病、偏頭痛和疼痛治療的可近性。巴西統一的公共醫療保健系統和地方法規結構具有廣泛的公共衛生意義，而墨西哥混合的醫療保健結構則造成了公共和私人管道之間不同的准入動態。

中樞神經系統（CNS）製藥業領導者使用的實用建議。

產業領導者應優先考慮差異化的臨床終點、基於生物標記的檢測設計以及真實世界數據 (RWE) 策略，以證明藥物能夠改善功能、提高安全性、延長療效持續時間並帶來有意義的患者結果。中樞神經系統 (CNS) 藥物研發公司可以透過與監管機構就適應性設計、分散式評估工具、數位生物標記、經驗證的療效指標、檢驗的患者分層以及證據預期等方面進行早期討論，來提高臨床實驗室的效率。

調查方法

本執行摘要是根據公開檢驗的二手資訊來源，包括衛生當局、同行評審的生物醫學文獻、監管公告、臨床實驗室註冊資訊、公共政策文件以及世界衛生組織（WHO）的資料編寫而成。重點參考了世界衛生組織（WHO）、美國食品藥物管理局（FDA）、歐洲資訊來源管理局（EMA）、美國國立衛生研究院（NIH）、經濟合作暨發展組織（OECD）、各國衛生機構、權威醫學期刊等機構的資料。

結論

中樞神經系統（CNS）藥物市場正向更實證和技術驅動的階段轉變。神經和精神疾病負擔日益加重、人口老化、診斷技術的進步以及生物標記的廣泛應用，為在神經病學、精神病學、疼痛管理和神經退化性疾病治療中帶來可衡量臨床獲益的療法創造了機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 中樞神經系統藥物市場：依藥物類別分類

  • 止痛藥
    • 非鴉片類鎮痛藥
    • 鴉片類鎮痛藥
  • 抗憂鬱症
  • 抗癲癇藥物
    • 鈣離子通道阻斷劑
    • GABA增強劑
    • 麩胺酸抑制劑
    • 鈉通道阻斷劑
  • 抗精神病藥物
    • 非典型
    • 固定形式
  • 抗焦慮藥物
    • 苯二氮平類藥物
    • 非苯二氮平類藥物
  • 中樞神經系統興奮劑
    • 安非他命
    • 哌甲酯
  • 催眠藥和鎮靜劑
    • 巴比妥類藥物
    • 苯二氮平類藥物
    • 非苯二氮平類藥物

第8章 中樞神經系統藥物市場：依劑型分類

  • 膠囊
    • 緩釋膠囊
    • 標準膠囊
  • 注射液
    • 肌肉內注射
    • IV
    • 皮下
  • 口服液
    • 懸浮液
    • 糖漿
  • 藥片
    • 緩釋片
    • 緩釋片
    • 標準鎖
  • 經皮吸收貼劑
    • 矩陣補丁
    • 水庫補丁

第9章 中樞神經系統藥物市場：依病患類型分類

  • 成人
  • 老年人
  • 兒童

第10章 中樞神經系統藥物市場：依作用機制分類

  • 膽鹼能
  • 多巴胺能
  • GABA能
  • 麩胺酸
  • 去甲腎上腺素能
  • 血清素活性

第11章 中樞神經系統藥物市場：依治療領域分類

  • ADHD
  • 阿茲海默症
  • 焦慮
  • 憂鬱症
  • 癲癇
  • 失眠
  • 偏頭痛
  • 疼痛
  • 帕金森氏症
  • 思覺失調症

第12章 中樞神經系統藥物市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 中樞神經系統藥物市場：依處方類型分類

  • 非處方藥
  • 複方藥物

第14章 中樞神經系統藥物市場：依銷售模式分類

  • 品牌
  • 非專利的

第15章 中樞神經系統藥物市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第16章 中樞神經系統藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 中樞神經系統藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • AbbVie Inc
  • Amatsigroup Co., Ltd.
  • Amgen Inc
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • CMIC Group Co., Ltd.
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Evotec SE
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc
  • Lonza Group AG
  • Merck & Co., Inc
  • Merck KGaA
  • Neurocrine Biosciences, Inc
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd
  • Patheon NV
  • Pfizer Inc
  • Recipharm AB
  • Samsung Biologics Co., Ltd.
  • Sanofi SA
  • Sumitomo Pharma Co., Ltd.
  • Takeda Pharmaceutical Company Ltd
  • Teva Pharmaceutical Industries Ltd
  • UCB SA
  • WuXi AppTec Co., Ltd.
Product Code: MRR-434CCDA05199

The Central Nervous System Drugs Market is projected to grow by USD 63.59 billion at a CAGR of 10.85% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 30.91 billion
Estimated Year [2026] USD 34.16 billion
Forecast Year [2032] USD 63.59 billion
CAGR (%) 10.85%

Executive Introduction to the Central Nervous System Drugs Market

Central nervous system drugs remain a critical pillar of global healthcare because neurological and psychiatric disorders represent a large, persistent, and clinically complex disease burden. The World Health Organization identifies neurological disorders as a leading cause of disability worldwide, while conditions such as depression, epilepsy, migraine, multiple sclerosis, Parkinson's disease, Alzheimer's disease, schizophrenia, and neuropathic pain continue to drive sustained treatment need.

The CNS drugs landscape is shaped by high unmet need, extended development timelines, stringent safety monitoring, and evolving standards for patient-centered outcomes. Momentum is supported by aging populations, wider diagnosis of mental health conditions, improved neuroimaging and biomarker use, and expanding access to specialty medicines. At the same time, payers and regulators are demanding clearer evidence of meaningful clinical benefit, durable response, functional improvement, and real-world safety.

Transformative Shifts in the CNS Drugs Landscape

The CNS drugs industry is moving from broad symptomatic treatment toward precision neurology and psychiatry. Advances in genetics, cerebrospinal fluid biomarkers, blood-based biomarkers, digital phenotyping, and imaging are improving patient stratification in diseases where heterogeneity has historically contributed to high trial failure rates.

Transformative shifts are also visible in therapeutic modalities. Small molecules continue to dominate many CNS categories due to blood-brain barrier considerations, but biologics, antisense oligonucleotides, gene therapies, radioligand approaches, neurostimulation-adjacent care models, and disease-modifying therapies are expanding clinical possibilities. Regulatory attention to accelerated pathways, post-marketing evidence, risk evaluation strategies, and patient-reported outcomes is reshaping how innovators design trials and commercialize CNS treatments.

Cumulative Impact of Artificial Intelligence on CNS Drug Development

Artificial intelligence is becoming cumulative in its impact across the CNS drugs value chain rather than functioning as a single-point tool. AI-enabled target discovery, protein-structure modeling, compound screening, and multi-omics analysis are helping researchers evaluate biological pathways linked to neurodegeneration, neuroinflammation, synaptic function, seizure biology, pain signaling, and psychiatric disease mechanisms.

In clinical development, machine learning supports site selection, patient matching, signal detection, adverse-event monitoring, imaging interpretation, and real-world evidence generation. CNS trials are particularly suited for AI augmentation because they often rely on complex clinical scales, imaging datasets, wearable-derived mobility data, speech patterns, sleep signals, cognitive assessments, and electronic health records. However, industry leaders must pair AI adoption with model validation, bias assessment, regulatory documentation, data privacy controls, cybersecurity safeguards, and clinical interpretability.

Key Regional Insights for CNS Drugs

North America remains a leading CNS drugs region due to advanced research infrastructure, high specialty medicine adoption, extensive clinical trial networks, and strong regulatory engagement through the U.S. Food and Drug Administration and Health Canada. The region benefits from broad neurology and psychiatry care capacity, active academic research centers, and growing use of real-world evidence to evaluate treatment safety and outcomes. Europe is similarly influential, supported by the European Medicines Agency, national reimbursement systems, large academic neurology networks, and rising investment in neurodegenerative disease research. Across Europe, health technology assessment bodies continue to place strong emphasis on comparative effectiveness, long-term safety, and demonstrable patient benefit.

Asia-Pacific is gaining strategic importance as China, Japan, India, South Korea, and Australia expand clinical trial participation, domestic innovation, and access to psychiatric and neurological care. The region's aging populations, expanding insurance coverage, and improving specialist infrastructure are increasing attention to Alzheimer's disease, Parkinson's disease, epilepsy, depression, migraine, and sleep disorders. Latin America shows improving demand for epilepsy, depression, migraine, and pain therapies, although reimbursement variability, diagnosis gaps, and uneven specialist access remain key constraints. The Middle East is increasing specialty care capacity in Gulf health systems through tertiary hospitals, digital health investment, and national mental health initiatives, while Africa presents long-term access opportunities as neurological diagnosis, mental health policy, workforce training, and essential medicine availability improve.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

The European Union provides one of the most structured regulatory and health technology assessment environments for CNS drugs, with growing emphasis on comparative effectiveness, pharmacovigilance, safety surveillance, and equitable access across member states. The G7 countries anchor much of the world's CNS research funding, pharmaceutical innovation, advanced care delivery, and regulatory science, making them central to adoption of disease-modifying therapies, specialty neurology treatments, and evidence-based mental health pharmacotherapy.

BRICS countries are increasingly important for patient diversity in clinical research, manufacturing capabilities, treatment access expansion, and healthcare infrastructure development, especially in China, India, and Brazil. ASEAN markets are improving neurological and mental healthcare infrastructure, with demand shaped by rising noncommunicable disease awareness, expanding hospital networks, and heterogeneous reimbursement and specialist availability. GCC countries are investing in tertiary care, digital health, rare disease programs, and specialty treatment access, supporting greater demand for advanced CNS therapies. NATO economies overlap significantly with high-income pharmaceutical markets where medicine supply resilience, strategic health security, cold-chain reliability, and continuity of care are receiving greater policy attention.

Key Country Insights for Priority CNS Drug Markets

The United States leads global CNS drug commercialization, clinical development, regulatory innovation, and premium specialty adoption, supported by deep capital markets, large clinical trial networks, and established Food and Drug Administration pathways. Canada emphasizes evidence-based reimbursement, health technology assessment, and access management, while Mexico and Brazil represent important Latin American markets where public and private systems shape uptake of epilepsy, psychiatric, migraine, and pain therapies. Brazil's unified public health system and local regulatory framework support broad public health relevance, while Mexico's mixed healthcare structure creates differentiated access dynamics across institutional and private channels.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are major CNS drug markets with strong clinical expertise, neurology research centers, and established psychiatric care pathways, although reimbursement timelines and assessment criteria vary by country. Germany's early benefit assessment process, the United Kingdom's cost-effectiveness evaluation, and France's clinical benefit review systems influence CNS launch strategies, while Italy and Spain balance regional access pathways with national reimbursement frameworks. Russia maintains domestic demand amid geopolitical and supply-chain complexity. China is accelerating CNS innovation and regulatory modernization, India combines a large patient base with strong generics manufacturing and expanding mental health awareness, Japan has high neurodegenerative disease relevance due to population aging, Australia offers sophisticated trial capacity and reimbursement evaluation, and South Korea is advancing biopharmaceutical innovation, digital health adoption, and specialty care access.

Actionable Recommendations for CNS Drug Industry Leaders

Industry leaders should prioritize differentiated clinical endpoints, biomarker-supported trial designs, and real-world evidence strategies that demonstrate functional improvement, safety, durability of response, and meaningful patient outcomes. CNS developers can improve trial productivity by using adaptive designs, decentralized assessment tools, digital biomarkers, validated rating scales, improved patient stratification, and earlier engagement with regulators on evidence expectations.

Commercial teams should align early with payers, clinicians, caregivers, and patient advocacy groups to define value in terms of disease progression, relapse reduction, cognition, mobility, seizure control, pain reduction, quality of life, caregiver burden, adherence, and healthcare resource utilization. Supply-chain resilience, pharmacovigilance excellence, inclusive trial recruitment, lifecycle evidence generation, and responsible AI governance should be treated as board-level priorities for sustainable CNS drug leadership.

Research Methodology

This executive summary is developed through secondary research using publicly available and verifiable sources, including health authorities, peer-reviewed biomedical literature, regulatory agency communications, clinical trial registries, public policy documents, and international health organizations. Priority was given to sources such as the World Health Organization, U.S. Food and Drug Administration, European Medicines Agency, National Institutes of Health, Organisation for Economic Co-operation and Development, national health agencies, and recognized medical journals.

The analysis synthesizes disease burden, regulatory trends, technology shifts, clinical development patterns, regional access dynamics, artificial intelligence adoption, and strategic implications. Insights are validated through triangulation across multiple data sources and presented in an structure for decision-makers evaluating the central nervous system drugs market, without relying on market sizing, market share, or forecast estimates.

Conclusion

The CNS drugs market is entering a more evidence-intensive and technology-enabled phase. Rising neurological and psychiatric disease burden, aging demographics, diagnostic advances, and growing use of biomarkers are creating opportunities for therapies that deliver measurable clinical benefit across neurology, psychiatry, pain management, and neurodegenerative care.

Success will depend on scientific differentiation, trial execution, regulatory credibility, market access planning, pharmacovigilance strength, and ethical use of artificial intelligence. Organizations that connect innovation with real-world patient needs, equitable access, and durable clinical outcomes will be best positioned to shape the next era of central nervous system therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Central Nervous System Drugs Market, by Drug Class

  • 7.1. Analgesic
    • 7.1.1. Non-Opioid Analgesic
    • 7.1.2. Opioid Analgesic
  • 7.2. Antidepressant
  • 7.3. Antiepileptic
    • 7.3.1. Calcium Channel Blocker
    • 7.3.2. Gaba Enhancer
    • 7.3.3. Glutamate Inhibitor
    • 7.3.4. Sodium Channel Blocker
  • 7.4. Antipsychotic
    • 7.4.1. Atypical
    • 7.4.2. Typical
  • 7.5. Anxiolytic
    • 7.5.1. Benzodiazepine
    • 7.5.2. Non-Benzodiazepine
  • 7.6. Cns Stimulant
    • 7.6.1. Amphetamines
    • 7.6.2. Methylphenidate
  • 7.7. Hypnotic And Sedative
    • 7.7.1. Barbiturates
    • 7.7.2. Benzodiazepine
    • 7.7.3. Non-Benzodiazepine Hypnotics

8. Central Nervous System Drugs Market, by Dosage Form

  • 8.1. Capsule
    • 8.1.1. Extended-Release Capsule
    • 8.1.2. Standard Capsule
  • 8.2. Injectable Solution
    • 8.2.1. IM
    • 8.2.2. IV
    • 8.2.3. Subcutaneous
  • 8.3. Oral Solution
    • 8.3.1. Suspension
    • 8.3.2. Syrup
  • 8.4. Tablet
    • 8.4.1. Delayed-Release Tablet
    • 8.4.2. Extended-Release Tablet
    • 8.4.3. Standard Tablet
  • 8.5. Transdermal Patch
    • 8.5.1. Matrix Patch
    • 8.5.2. Reservoir Patch

9. Central Nervous System Drugs Market, by Patient Type

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Central Nervous System Drugs Market, by Mechanism Of Action

  • 10.1. Cholinergic
  • 10.2. Dopaminergic
  • 10.3. Gabaergic
  • 10.4. Glutamatergic
  • 10.5. Noradrenergic
  • 10.6. Serotonergic

11. Central Nervous System Drugs Market, by Therapeutic Area

  • 11.1. ADHD
  • 11.2. Alzheimer's Disease
  • 11.3. Anxiety
  • 11.4. Depression
  • 11.5. Epilepsy
  • 11.6. Insomnia
  • 11.7. Migraine
  • 11.8. Pain
  • 11.9. Parkinson's Disease
  • 11.10. Schizophrenia

12. Central Nervous System Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Central Nervous System Drugs Market, by Prescription Type

  • 13.1. Over The Counter
  • 13.2. Prescription

14. Central Nervous System Drugs Market, by Sales Model

  • 14.1. Branded
  • 14.2. Generic

15. Central Nervous System Drugs Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. North America
  • 15.3. Latin America
  • 15.4. Europe
  • 15.5. Middle East
  • 15.6. Africa

16. Central Nervous System Drugs Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Central Nervous System Drugs Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. AbbVie Inc
  • 19.2. Amatsigroup Co., Ltd.
  • 19.3. Amgen Inc
  • 19.4. AstraZeneca plc
  • 19.5. Bayer AG
  • 19.6. Biogen Inc
  • 19.7. Boehringer Ingelheim International GmbH
  • 19.8. Bristol-Myers Squibb Company
  • 19.9. CMIC Group Co., Ltd.
  • 19.10. Daiichi Sankyo Company, Limited
  • 19.11. Eisai Co., Ltd.
  • 19.12. Eli Lilly and Company
  • 19.13. Evotec SE
  • 19.14. F. Hoffmann-La Roche Ltd
  • 19.15. GlaxoSmithKline plc
  • 19.16. H. Lundbeck A/S
  • 19.17. Johnson & Johnson Services, Inc
  • 19.18. Lonza Group AG
  • 19.19. Merck & Co., Inc
  • 19.20. Merck KGaA
  • 19.21. Neurocrine Biosciences, Inc
  • 19.22. Novartis AG
  • 19.23. Otsuka Pharmaceutical Co., Ltd
  • 19.24. Patheon N.V.
  • 19.25. Pfizer Inc
  • 19.26. Recipharm AB
  • 19.27. Samsung Biologics Co., Ltd.
  • 19.28. Sanofi S.A.
  • 19.29. Sumitomo Pharma Co., Ltd.
  • 19.30. Takeda Pharmaceutical Company Ltd
  • 19.31. Teva Pharmaceutical Industries Ltd
  • 19.32. UCB S.A.
  • 19.33. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANALGESIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANALGESIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANALGESIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NON-OPIOID ANALGESIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-OPIOID ANALGESIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NON-OPIOID ANALGESIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OPIOID ANALGESIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OPIOID ANALGESIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OPIOID ANALGESIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIDEPRESSANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIDEPRESSANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIDEPRESSANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIEPILEPTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIEPILEPTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIEPILEPTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CALCIUM CHANNEL BLOCKER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CALCIUM CHANNEL BLOCKER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CALCIUM CHANNEL BLOCKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GABA ENHANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GABA ENHANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GABA ENHANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GLUTAMATE INHIBITOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GLUTAMATE INHIBITOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GLUTAMATE INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SODIUM CHANNEL BLOCKER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SODIUM CHANNEL BLOCKER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SODIUM CHANNEL BLOCKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIPSYCHOTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIPSYCHOTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIPSYCHOTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ATYPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ATYPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ATYPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TYPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TYPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TYPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANXIOLYTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANXIOLYTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANXIOLYTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BENZODIAZEPINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BENZODIAZEPINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BENZODIAZEPINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NON-BENZODIAZEPINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NON-BENZODIAZEPINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NON-BENZODIAZEPINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CNS STIMULANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CNS STIMULANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CNS STIMULANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AMPHETAMINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AMPHETAMINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AMPHETAMINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL METHYLPHENIDATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL METHYLPHENIDATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL METHYLPHENIDATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HYPNOTIC AND SEDATIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HYPNOTIC AND SEDATIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HYPNOTIC AND SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BARBITURATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BARBITURATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BARBITURATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BENZODIAZEPINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BENZODIAZEPINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BENZODIAZEPINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NON-BENZODIAZEPINE HYPNOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NON-BENZODIAZEPINE HYPNOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NON-BENZODIAZEPINE HYPNOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL EXTENDED-RELEASE CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL EXTENDED-RELEASE CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL EXTENDED-RELEASE CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL STANDARD CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL STANDARD CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL STANDARD CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INJECTABLE SOLUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INJECTABLE SOLUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INJECTABLE SOLUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ORAL SOLUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ORAL SOLUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ORAL SOLUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SUSPENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SUSPENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SUSPENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SYRUP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SYRUP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SYRUP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL TABLET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TABLET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DELAYED-RELEASE TABLET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DELAYED-RELEASE TABLET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DELAYED-RELEASE TABLET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL EXTENDED-RELEASE TABLET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL EXTENDED-RELEASE TABLET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL EXTENDED-RELEASE TABLET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL STANDARD TABLET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL STANDARD TABLET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL STANDARD TABLET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL TRANSDERMAL PATCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL TRANSDERMAL PATCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL TRANSDERMAL PATCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MATRIX PATCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL MATRIX PATCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL MATRIX PATCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL RESERVOIR PATCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL RESERVOIR PATCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL RESERVOIR PATCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CHOLINERGIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CHOLINERGIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CHOLINERGIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL DOPAMINERGIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL DOPAMINERGIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL DOPAMINERGIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL GABAERGIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL GABAERGIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL GABAERGIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL GLUTAMATERGIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL GLUTAMATERGIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL GLUTAMATERGIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL NORADRENERGIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL NORADRENERGIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL NORADRENERGIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL SEROTONERGIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL SEROTONERGIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL SEROTONERGIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ADHD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ADHD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ADHD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANXIETY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ANXIETY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANXIETY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL DEPRESSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL DEPRESSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL DEPRESSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL EPILEPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL EPILEPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL EPILEPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL INSOMNIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL INSOMNIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL INSOMNIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL MIGRAINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL MIGRAINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL MIGRAINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL PAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL PAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL PAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL SCHIZOPHRENIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL SCHIZOPHRENIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL SCHIZOPHRENIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL OVER THE COUNTER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL OVER THE COUNTER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL OVER THE COUNTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL PRESCRIPTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL PRESCRIPTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL PRESCRIPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL BRANDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL GENERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 236. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2018-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2018-2032 (USD MILLION)
  • TABLE 250. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2018-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2018-2032 (USD MILLION)
  • TABLE 252. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2018-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2018-2032 (USD MILLION)
  • TABLE 254. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 256. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 258. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 260. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 262. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 286. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 288. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2018-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2018-2032 (USD MILLION)
  • TABLE 290. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2018-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2018-2032 (USD MILLION)
  • TABLE 292. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2018-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2018-2032 (USD MILLION)
  • TABLE 294. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 296. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 298. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 300. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 302. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 304. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 306. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 307. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 308. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2018-2032 (USD MILLION)
  • TABLE 309. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2018-2032 (USD MILLION)
  • TABLE 310. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2018-2032 (USD MILLION)
  • TABLE 311. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2018-2032 (USD MILLION)
  • TABLE 312. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2018-2032 (USD MILLION)
  • TABLE 313. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2018-2032 (USD MILLION)
  • TABLE 314. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 315. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 316. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 317. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 318. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 319. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 320. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 322. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 323. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 324. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 326. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 327. ASEAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 328. ASEAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 329. ASEAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2018-2032 (USD MILLION)
  • TABLE 330. ASEAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2018-2032 (USD MILLION)
  • TABLE 331. ASEAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2018-2032 (USD MILLION)
  • TABLE 332. ASEAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2018-2032 (USD MILLION)
  • TABLE 333. ASEAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2018-2032 (USD MILLION)
  • TABLE 334. ASEAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2018-2032 (USD MILLION)
  • TABLE 335. ASEAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 336. ASEAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 337. ASEAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 338. ASEAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 339. ASEAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 340. ASEAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 341. ASEAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. ASEAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 343. ASEAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 344. ASEAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 345. ASEAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 346. ASEAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 347. GCC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 348. GCC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 349. GCC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2018-2032 (USD MILLION)
  • TABLE 350. GCC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2018-2032 (USD MILLION)
  • TABLE 351. GCC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2018-2032 (USD MILLION)
  • TABLE 352. GCC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2018-2032 (USD MILLION)
  • TABLE 353. GCC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2018-2032 (USD MILLION)
  • TABLE 354. GCC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2018-2032 (USD MILLION)
  • TABLE 355. GCC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 356. GCC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 357. GCC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 358. GCC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 359. GCC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 360. GCC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 361. GCC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 362. GCC CENTRAL NERVOUS SYSTE